It feels like NWBO and friends can make the same if they accumulate more share/ownership % while pharma then can get lower/competitive BO price, while those outside such potential symbiosis are shaked and baked. Feels like that. You know the refrain “cut out middle management?” Instead, here it feels like “cut out retail.”